Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 50 Women only

Examining how exenatide works in pregnant women with gestational diabetes

Official title: Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Run by University of Pittsburgh · NCT05482789 · Data updated 2026-11-12

This study is testing how well the diabetes drug exenatide works in pregnant women with gestational diabetes to see if it can help control their blood sugar levels better.

More Gestational Diabetes trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 50 Years
SexWomen only
Enrollment13 (estimated)
SponsorUniversity of Pittsburgh
Academic / other
Locations1 site (Pittsburgh, Pennsylvania)
StatusRecruiting
StartedApril 12, 2023
Main results expectedDecember 31, 2025
Study endsDecember 31, 2026
Registry record updatedApril 20, 2026
Trial IDNCT05482789 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women aged 18 to 50 with gestational diabetes that does not require medical therapy.

Probably not a fit

Patients who are in their first trimester of pregnancy or have a history of gastrointestinal disease or renal insufficiency may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the pharmacokinetics and pharmacodynamics of exenatide, a drug approved for type II diabetes, in pregnant women diagnosed with gestational diabetes. The research aims to understand how the body processes exenatide and its effectiveness in stimulating insulin secretion and controlling blood sugar levels after meals. Currently, there are limited treatment options for gestational diabetes, and this study seeks to explore a potential alternative therapy that may improve blood sugar management for affected women.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for managing blood sugar levels in pregnant women with gestational diabetes.

How similar studies have gone: While there are limited studies specifically on exenatide for gestational diabetes, the use of similar pharmacological approaches in other populations has shown promise.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pregnant women (singleton)
* Gestational diabetes not requiring medical therapy
* Between 18 and 50 years of age
* Able to give written informed consent

Exclusion Criteria:

* Women in the first trimester of pregnancy
* Hematocrit less than 30%
* Current or past treatment with any hypoglycemic agent
* Women with gastrointestinal disease or symptoms consistent with nausea, vomiting, abdominal pain or reflux requiring medical treatment.
* Women with high triglyceride levels, history of gallbladder or pancreatic disease.
* Clinical diagnosis or history of any renal insufficiency (or decreased creatinine clearance)

Where it's running

  • Magee Womens Hospital of UPMC
    Pittsburgh, Pennsylvania, United States
    Recruiting

Study contacts

  • Principal investigator: Maisa Feghali, MD — University of Pittsburgh
  • Study coordinator: Maisa Feghali, MD
  • Email: feghalim@upmc.edu
  • Phone: 412 647 1000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.